Blue Jet Healthcare Ltd (NSE: BLUEJET) and Concord Biotech Ltd (NSE: CONCORDBIO) are both listed in the Pharmaceutical CDMO and CRO Services industry. Blue Jet Healthcare has a market capitalisation of ₹9,353 Cr and Concord Biotech ₹12,172 Cr, as of 9 Nov 2026. Their P/E ratios are 34.6 and 46.7 respectively. Return on equity is 19.88% for Blue Jet Healthcare and 13.54% for Concord Biotech. Over one year, Blue Jet Healthcare's share price is down 19.6% and Concord Biotech's is down 18.6%.
| Metric | Blue Jet Healthcare | Concord Biotech |
|---|---|---|
| NSE Symbol | BLUEJET | CONCORDBIO |
| BSE Code | 544009 | 543960 |
| Share Price | ₹541.90 | ₹598.40 |
| Market Cap | ₹9,353 Cr | ₹12,172 Cr |
| P/E Ratio | 34.6 | 46.7 |
| Return on Equity | 19.88% | 13.54% |
| Return on Assets | 11.24% | 8.91% |
| Dividend Yield | 0.24% | 0.65% |
| Beta (1Y) | 0.89 | 0.17 |
| 1-Year Price Change | -19.6% | -18.6% |
| 3-Month Price Change | -8.5% | -15.7% |
| 52-Week Range | ₹325.00 – ₹647.80 | ₹493.50 – ₹807.50 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹376 Cr | ₹309 Cr |
| Quarterly Net Profit | ₹103 Cr | ₹70 Cr |
| Net Margin | 27.3% | 22.5% |
| EPS (Basic, Quarter) | ₹5.46 | ₹6.65 |
| Results Basis | standalone | consolidated |
| Headquarters | Thane, Maharashtra | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and …
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinom…
Concord Biotech has a market capitalisation of ₹12,172 Cr, against ₹9,353 Cr for Blue Jet Healthcare as of 9 Nov 2026, about 1.3 times the size by market cap.
Blue Jet Healthcare has a P/E of 34.6 and Concord Biotech a P/E of 46.7 as of 9 Nov 2026.
Blue Jet Healthcare has a return on equity of 19.88% and Concord Biotech 13.54%.
Blue Jet Healthcare's share price is down 19.6% over one year and Concord Biotech's is down 18.6%.
Blue Jet Healthcare reported revenue of ₹376 Cr and net profit of ₹103 Cr for Q2 FY27. Concord Biotech reported revenue of ₹309 Cr and net profit of ₹70 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.